Diagnosed Before Dupixent? The Delayed-Diagnosis Claim Explained

The Question We Hear Most Often

People who contact us about Dupixent (dupilumab) and cutaneous T-cell lymphoma frequently open with a version of the same sentence: “I don’t think I qualify, because my lymphoma was found while I was still on the drug” — or, sometimes, “my dermatologist thinks I probably had it before I ever started.”

That assumption is worth pausing on. The lawsuits filed to date against Sanofi and Regeneron plead two distinct theories, and only one of them depends on the drug having started a cancer that was not there before. A post — or a conversation — that covers only the first theory gives an incomplete picture of who the litigation is written to include.

This article walks through both theories, in plain language, and explains why the timing of a diagnosis is a question for the records and the experts rather than something a patient should decide against themselves at the outset.

Two Theories, Not One

The complaints reported to date advance these allegations:

1. A causation theory. That treatment with dupilumab may cause or accelerate the progression of a cutaneous T-cell lymphoma — including mycosis fungoides and Sézary syndrome — in patients treated for eczema or atopic dermatitis.

2. A masking or delayed-diagnosis theory. That the drug may suppress or soften the skin symptoms of a lymphoma the patient already had, so that the disease is not recognized for what it is until later, at a more advanced stage.

Both are allegations under examination in active litigation. Neither has been established as a proven biological mechanism, and no court has determined that dupilumab causes, accelerates, or conceals lymphoma in anyone. Reported filings, including one described by AboutLawsuits.com as alleging that Dupixent “caused T-cell lymphoma or rapidly progressed” an existing cancer, reflect what plaintiffs claim — not what has been decided.

Why Eczema and Early CTCL Look Alike

The delayed-diagnosis theory rests on a clinical reality that dermatologists have written about for decades, entirely apart from any lawsuit: early cutaneous T-cell lymphoma is genuinely difficult to distinguish from stubborn eczema or psoriasis.

Early-stage mycosis fungoides, the most common form of CTCL, often appears as flat, scaly, itchy patches on skin that ordinarily stays covered. It can wax and wane. It can respond, at least partly, to topical steroids. Patients are commonly treated for inflammatory skin disease for years before a biopsy returns a lymphoma diagnosis. The National Cancer Institute maintains general patient information on cutaneous T-cell lymphomas, including how they are staged and treated.

That diagnostic overlap is the backdrop for the second theory. Plaintiffs allege that when a treatment substantially improves the appearance of the skin, the visible signal a clinician relies on to decide whether to biopsy may become harder to read. Again — that is the allegation, offered as the reason a diagnosis arrived when it did, and it is contested.

What “Masking” Would Have to Show

It is fair to ask what a delayed-diagnosis claim actually requires. Broadly, and without predicting how any court will rule, this limb of the litigation turns on questions like:

• What the skin disease looked like, and how it behaved, before dupilumab was started
• Whether biopsies were taken, when, and what they showed
• How the presentation changed during treatment
• What stage the lymphoma had reached by the time it was identified
• Whether the manufacturers knew of, and adequately communicated, any signal relevant to that sequence

Notice that almost none of that is something a patient can assess from memory. It lives in pathology reports, dermatology notes, and pharmacy records.

Why a Pre-Treatment Diagnosis Isn’t an Automatic Exclusion

Here is the practical consequence: someone whose lymphoma was diagnosed before starting Dupixent is not automatically outside this litigation.

Under the acceleration and delayed-diagnosis allegations, the claimed harm is not limited to the creation of a new cancer. It also includes an alleged worsening of the course of a disease that already existed, or a delay in recognizing it. Whether the facts of any individual case actually support that is a question for medical experts, and many cases reviewed under this theory will not proceed. But the screening question is not simply “did the cancer come first?”

The same is true in the other direction. A diagnosis that came years after the last injection is not disqualified by the gap alone; latency is itself a disputed issue in this litigation.

Where the Litigation Actually Stands

Dupixent CTCL cases have been centralized before a single federal judge for coordinated pretrial handling — a step taken by the Judicial Panel on Multidistrict Litigation, with the proceeding assigned to the U.S. District Court for the District of New Jersey.

It is important to be precise about what that means. Centralization is a case-management decision. The panel that orders it is deciding that cases share enough common factual questions to be handled efficiently in one place. It is not a finding that the drug caused anything, not an endorsement of the plaintiffs’ theories, and not a signal about how any case will end.

This litigation is also early. There is very little established fact — no bellwether trial record, no set of scientific conclusions the parties agree on, and no basis on which anyone should be projecting how it will grow or what individual claims might be worth. Be skeptical of any source that offers you those numbers.

What the Regulators Have Said

Dupixent remains an approved prescription medication, and for many people with severe atopic dermatitis it has been an effective one. Nothing here is a recommendation to stop taking a prescribed drug — that decision belongs to you and your physician, and stopping abruptly carries its own risks.

Current prescribing information, approval history, and any adverse-event reporting for approved products are published by the FDA, and the agency’s MedWatch program is where patients and clinicians can report suspected adverse events. Published research on dupilumab and cutaneous T-cell lymphoma — including case reports and case series that describe associations, not proven causation — can be searched through PubMed. The published literature at this point is limited and does not establish that the drug causes lymphoma.

The Records That Decide This

If you are trying to work out whether the timeline in your own case matters, these are the documents that carry the weight:

• Dermatology and pathology records, especially every skin biopsy report and the dates they were taken
• The full treatment history for eczema or atopic dermatitis, including what was tried before dupilumab
• Pharmacy and specialty-pharmacy records showing when Dupixent was dispensed and for how long
• Oncology and staging records from the point of the lymphoma diagnosis forward

If some of these are missing or scattered across health systems, that is normal and it is not a reason to hold off. Records can be requested. You do not need to have them organized before speaking with someone.

You can read more about how these cases are being evaluated on our Dupixent lymphoma page.

Take the Next Step

If you or someone in your family was treated with Dupixent for eczema or atopic dermatitis and has been diagnosed with cutaneous T-cell lymphoma, mycosis fungoides, or Sézary syndrome, the sequence of events deserves a careful look — including if the diagnosis came before or during treatment rather than after it.

We review these timelines at no cost and with no obligation, and we will tell you plainly if the facts do not support a claim. Legal deadlines vary by state and can run from dates that are not obvious, so it is worth asking sooner rather than later.

Request a free case review to have your treatment and diagnosis history evaluated.

This article is general information, not legal or medical advice, and does not create an attorney-client relationship. Every allegation described here is a claim made in pending litigation that has not been proven. Do not change or stop a prescribed medication without talking to your physician.